Abstract
Neurodegenerative diseases cause progressive and irreversible loss of cognitive and motor activity. Most common are Alzheimer’s disease (AD) and Parkinson’s disease (PD), which are the key reason of dementia and movement disorder, respectively. Current state-of-the-art technologies relies on spinal tap and imaging techniques, which delays the diagnosis till advanced stage. Early detection of diseases using blood or non-invasive biomarkers shows potential for clinical management of disease progression and open new avenue for assessing pharmacological effects of novel treatments. This work presents a point-of-care graphene field effect transistor-based detection of p-Tau 217 and α-Synuclein monomer for Alzheimer’s disease and Parkinson’s disease detection, respectively.
